Jacobs Levy Equity Management Inc. Cuts Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS)

Jacobs Levy Equity Management Inc. trimmed its stake in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) by 18.7% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,534,668 shares of the company’s stock after selling 352,844 shares during the period. Jacobs Levy Equity Management Inc. owned 0.68% of Gossamer Bio worth $1,388,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its stake in Gossamer Bio by 1.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company’s stock valued at $1,123,000 after acquiring an additional 13,902 shares in the last quarter. Silverarc Capital Management LLC grew its stake in Gossamer Bio by 9.3% during the fourth quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company’s stock valued at $5,583,000 after acquiring an additional 526,495 shares in the last quarter. Allostery Investments LP purchased a new position in Gossamer Bio during the fourth quarter valued at $555,000. Alyeska Investment Group L.P. grew its stake in Gossamer Bio by 52.7% during the fourth quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company’s stock valued at $7,968,000 after acquiring an additional 3,041,058 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Gossamer Bio by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company’s stock valued at $2,037,000 after acquiring an additional 38,084 shares in the last quarter. 81.23% of the stock is owned by hedge funds and other institutional investors.

Gossamer Bio Stock Performance

Shares of NASDAQ:GOSS opened at $1.04 on Friday. Gossamer Bio, Inc. has a 52 week low of $0.50 and a 52 week high of $1.55. The stock has a market capitalization of $236.31 million, a P/E ratio of -3.25 and a beta of 1.82. The firm has a fifty day simple moving average of $1.04 and a two-hundred day simple moving average of $0.99. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The firm had revenue of $9.89 million for the quarter, compared to analysts’ expectations of $3.95 million. On average, analysts expect that Gossamer Bio, Inc. will post -0.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on GOSS shares. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Gossamer Bio in a research note on Tuesday, March 18th. Wedbush reissued an “outperform” rating and issued a $4.00 price objective on shares of Gossamer Bio in a research note on Friday. Finally, The Goldman Sachs Group lifted their price objective on shares of Gossamer Bio from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.